Streetbeat News

Stock Prices

NVO

The European Medicines Agency's CHMP has given a positive opinion for updating Novo Nordisk's Wegovy label to include data showing benefits for obesity-related heart failure. This update is based on trials showing Wegovy's effectiveness in reducing heart failure symptoms and improving physical function. Novo Nordisk plans to resubmit this data to the FDA in 2025.

Portfolio Pulse from Vandana Singh

September 20, 2024 | 12:08 pm

ATNM

Actinium Pharmaceuticals has published the results of its Phase 3 SIERRA trial for Iomab-B in the Journal of Clinical Oncology. The trial highlights the success of Iomab-B in achieving complete remission and event-free survival.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2024 | 12:05 pm

DOGEUSD

SHIBUSD

Pepe (PEPE) has outperformed Dogecoin (DOGE) and Shiba Inu (SHIB) in recent gains and trading volume, signaling a potential 'meme season' in the crypto market. Traders predict further growth for PEPE, possibly reaching a $10 billion market cap.

Portfolio Pulse from Khyathi Dalal

September 20, 2024 | 12:05 pm

KOPN

Kopin Corporation has announced a $27 million public offering of common stock and pre-funded warrants, with the closing expected around September 23.

Portfolio Pulse from Nabaparna Bhattacharya

September 20, 2024 | 12:04 pm

GLE

Global Engine Group has announced the pricing of its $8 million Initial Public Offering (IPO) at $4.00 per share.

Portfolio Pulse from Nabaparna Bhattacharya

September 20, 2024 | 12:02 pm

LH

Labcorp Holdings (NYSE:LH) has been analyzed by 9 analysts, showing a range of ratings from bullish to indifferent. Recent analyst actions have predominantly raised price targets, with an average target of $257.67, up from $243.89. Labcorp's financial metrics, such as revenue growth and net margin, are strong, though its growth rate lags behind peers.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 12:01 pm

AEIS

Analysts have mixed ratings for Advanced Energy Industries (NASDAQ:AEIS), with recent assessments showing a range from bullish to indifferent. The average 12-month price target has increased by 13.15% to $117.0. Despite a revenue decline of 12.17%, AEIS maintains strong net margins and ROE, but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 12:01 pm

AMKR

In the past three months, four analysts have rated Amkor Technology (NASDAQ:AMKR), with opinions ranging from bullish to indifferent. The average 12-month price target has increased by 14.19% to $42.25. Analysts have adjusted their ratings and price targets, reflecting their views on Amkor's market position and financial performance.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 12:00 pm

IQV

The article provides an overview of recent analyst recommendations for IQVIA Holdings (NYSE:IQV), highlighting a range of sentiments from bullish to bearish. Over the last three months, 13 analysts have shared their evaluations, with the majority being somewhat bullish. The average 12-month price target has increased to $265.92. Key financial metrics such as revenue growth, net margin, and return on equity are strong, but the company has a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 12:00 pm

CRL

Charles River Laboratories (NYSE:CRL) has been analyzed by 10 analysts, showing a range of opinions from bullish to bearish. Recent analyst actions have predominantly lowered price targets, with the average target now at $218.3, down 13.6% from a previous $252.67. Despite revenue challenges, Charles River shows strong financial health with high net margins, ROE, and ROA, and a conservative debt approach.

Portfolio Pulse from Benzinga Insights

September 20, 2024 | 12:00 pm